Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 10:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–40 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Visudyne Clear all
Completed Phase 2 Interventional

Treatment of Age-Related Macular Degeneration With Anecortave Acetate

NCT00211458
View directory record Official record
Conditions
Macular Degeneration
Interventions
Anecortave Acetate Sterile Suspension (15 mg)
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
50 Years and older
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Sep 9, 2026, 10:27 PM EDT
Recruiting Phase 1Phase 2 Interventional

Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction

NCT06306638
View directory record Official record
Conditions
Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Computed Tomography, Endobronchial Ultrasound Bronchoscopy, Interstitial Photodynamic Therapy, Palliative Radiation Therapy, Physical Performance Testing, Questionnaire Administration, Verteporfin, Laser: ML7710-PDT
Procedure · Radiation · Other + 2 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Buffalo, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 9, 2026, 10:27 PM EDT
Completed Phase 1 Interventional

Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)

NCT00211419
View directory record Official record
Conditions
Maculopathy, Age-Related
Interventions
Anecortave Acetate 15 mg, Triamcinolone Acetate 4 mg, Photodynamic Therapy with Verteporfin, Thermal Laser
Drug · Procedure
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Sep 9, 2026, 10:27 PM EDT
Completed Phase 2 Interventional

Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD

NCT00426998
View directory record Official record
Conditions
Choroidal Neovascularization, Macular Degeneration
Interventions
Verteporfin, Bevacizumab
Drug
Lead sponsor
Retinal Consultants Medical Group
Other
Eligibility
55 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2007 · Synced Sep 9, 2026, 10:27 PM EDT
Withdrawn Not applicable Interventional

Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD

NCT02457026
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Aflibercept, Triamcinolone Acetonide, Verteporfin
Drug
Lead sponsor
Duke University
Other
Eligibility
55 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 9, 2026, 10:27 PM EDT
Completed Phase 4 Interventional

Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment

NCT00680498
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Ranibizumab, Ranibizumab plus Photodynamic therapy
Drug
Lead sponsor
Illinois Retina Associates
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Oak Park, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 27, 2012 · Synced Sep 9, 2026, 10:27 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy

NCT01469156
View directory record Official record
Conditions
Polypoidal Choroidal Vasculopathy
Interventions
ranibizumab 0.5 or 2.0 mg/0.05 cc
Drug
Lead sponsor
Southeast Retina Center, Georgia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 11, 2022 · Synced Sep 9, 2026, 10:27 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

ICG-Guided Photodynamic Therapy for Treatment of Retinal Capillary Abnormalities: A Pilot Study

NCT01974622
View directory record Official record
Conditions
Retinal Vascular Disorders
Interventions
Visudyne
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Sep 9, 2026, 10:27 PM EDT
Completed Phase 2 Interventional

Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration

NCT00390208
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
ranibizumab, dexamethasone and verteporfin, Ranibizumab
Drug
Lead sponsor
Bay Area Retina Associates
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Castro Valley, California • Walnut Creek, California • Riverdale, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated May 26, 2010 · Synced Sep 9, 2026, 10:27 PM EDT
Active, not recruiting Phase 2 Interventional

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

NCT06381154
View directory record Official record
Conditions
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Endoscopic Ultrasound, Fluorouracil, Irinotecan, Leucovorin, Lymph Node Biopsy, Magnetic Resonance Imaging, Oxaliplatin, Pembrolizumab, Photodynamic Therapy, Positron Emission Tomography, Questionnaire Administration, Verteporfin
Procedure · Drug · Biological + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 9, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study Of Combined VISUDYNE Therapy With Kenalog In CNV Secondary To Age-Related Macular Degeneration

NCT00140803
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Visudyne, Kenalog
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
50 Years and older
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 11, 2007 · Synced Sep 9, 2026, 10:27 PM EDT
Completed Phase 3 Interventional

Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration

NCT00100009
View directory record Official record
Conditions
Macular Degeneration
Interventions
TAC-PF, Triamcinolone Acetonide
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
23
States / cities
Tucson, Arizona • Los Angeles, California • Miami, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 9, 2026, 10:27 PM EDT
Terminated Not applicable Interventional

Macugen for Histoplasmosis

NCT00272766
View directory record Official record
Conditions
Ocular Histoplasmosis, Choroidal Neovascularization
Interventions
pegaptanib sodium
Drug
Lead sponsor
Barnes Retina Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 26, 2006 · Synced Sep 9, 2026, 10:27 PM EDT
Terminated Phase 2 Interventional

TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration

NCT00464347
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Avastin, Photodynamic Therapy (PDT), Preservative-Free Triamcinolone Acetonide (TAC-PF)
Drug · Procedure
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
11
States / cities
Fort Lauderdale, Florida • Orlando, Florida • Pensacola, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2010 · Synced Sep 9, 2026, 10:27 PM EDT
Recruiting Phase 1Phase 2 Interventional

Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System

NCT06807359
View directory record Official record
Conditions
Prostate Cancer
Interventions
Photodynamic Therapy (PDT), Verteporfin Injection
Device · Drug
Lead sponsor
SpectraCure AB
Industry
Eligibility
18 Years and older · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 9, 2026, 10:27 PM EDT
Recruiting Phase 1Phase 2 Interventional

Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma

NCT04590664
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma
Interventions
Verteporfin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Sep 9, 2026, 10:27 PM EDT